Predictive Value of eIF4E Reduction After Neoadjuvant Therapy in Breast Cancer

Journal of Surgical Research

Volumn 156, Issue 2, 2009, Pages 265-269

  Hiller, David J ^a   Chu, Quyen ^a   Meschonat, Carol ^a   Panu, Lori ^a   Burton, Gary ^a   Li, Benjamin D L ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

cancer response; eIF4E; neoadjuvant therapy; prognostic marker; therapeutic marker

Indexed keywords

ANASTROZOLE; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; INITIATION FACTOR 4E; METHOTREXATE; PACLITAXEL; ZOLEDRONIC ACID;

ADULT; ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; DRUG EFFECT; FOLLOW UP; HUMAN; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN DETERMINATION; WESTERN BLOTTING;

ADULT; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; EUKARYOTIC INITIATION FACTOR-4E; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 70249117786     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2009.03.060     Document Type: Article

References (25)

1. Moulder S., and Hortobagyi G.N. Advances in treatment of breast cancer. Clinical Pharm Therpaeut 83 (2003) 26
2. Berry D.A., Cronin K.A., Plevritis S.K., et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353 (2005) 1784
3. National Cancer Institute. Cancer Trends Progress Report-2007 Update. Bethesda, MD: NIH, DHHS, December, 2007. Available at: http://www.progressreport.cancer.gov. Accessed December 29, 2008.
4. Osborne C.K. Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat 51 (1998) 227
5. Nahta R., and Esteva F.J. Trastuzumab: Triumphs and tribulations. Oncogene 26 (2007) 3637
6. Cance W.G., Carey L.A., Calvo B.F., et al. Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma. Ann Surg 236 (2005) 295
7. Powles T.J., Hickish T.F., Makris A., et al. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 13 (1995) 547
8. Carlson R.W., and Favret A.M. Multidisciplinary management of locally advanced breast cancer. Breast J 5 (1999) 303
9. Scholl S.M., Pierga J.Y., Asselain B., et al. Breast tumor response to primary chemotherapy predicts local and distant control as well as survival. Eur J Cancer 31 (1995) 1969
10. Kuerer H.M., Hunt K.K., Newman L.A., et al. Neoadjuvant chemotherapy in women with invasive breast carcinoma: Conceptual basis and fundamental surgical issues. J Am Coll Surg 190 (2000) 350
11. Rosenwald I.B., Lazaris-Karatzas A., Sonenberg N., et al. Elevated levels of cyclin D1 in response to increased expression of eukaryotic initiation factor 4E. Mol Cell Biol 13 (1993) 7358
12. Kevil C.G., De Benedetti A., Payne D.K., et al. Translational regulation of vascular permeability factor by eukaryotic initiation factor 4E: Implications for tumor angiogenesis. Int J Cancer 65 (1996) 786
13. Kevil C., Carter P., Hu B., et al. Translational enhancement of FGF-2 by eIF-4 factors, and alternate utilization of CUG and AUG codons for translation initiation. Oncogene 11 (1995) 2339
14. Li Y., DeFatta R., Anthony C., et al. A translationally regulated tousled kinase phosphorylates histone H3 and confers radioresistance when overexpressed. Oncogene 20 (2001) 726
15. Norton K.S., McClusky D., Sen S., et al. TLK1B is elevated with eIF4E overexpression in breast cancer. J Surg Res 116 (2004) 98
16. Sunavala-Dossabhoy G., Balakrishnan S.K., and De Benedetti A. The radioresistance kinase TLK1B protects the cells by promoting repair of double strand breaks. BMC Mol Biol 6 (2005) 19
17. Byrnes K.W., De Benedetti A., Holm N.T., et al. Correlation of TLK1B in elevation and recurrence in doxorubicin-treated breast cancer patients with high eIF4E overexpression. J Am Coll Surg 204 (2007) 925
18. McClusky D.R., Chu Q., Yu H., et al. A prospective trial on initiation factor 4E (eIF4E) overexpression and cancer recurrence in node-positive breast cancer. Ann Surg 242 (2005) 584
19. Holm N., Byrnes K., Johnson L., et al. A prospective trial on initiation factor 4E (eIF4E) overexpression and cancer recurrence in node-negative breast cancer. Ann Surg Oncol 15 (2008) 3207
20. Li B.D., Gruner J.S., Abreo F., et al. Prospective study of eukaryotic initiation factor 4E protein elevation and breast cancer outcome. Ann Surg 235 (2002) 732
21. Li B.D., McDonald J.C., Nassar R., et al. Clinical outcome in stage I to III breast carcinoma and eIF4E overexpression. Ann Surg 227 (1998) 756
22. Kerekatte V., Smiley K., Hu B., et al. The proto-oncogene/translation factor eIF4E: A survey of its expression in breast carcinomas. Int J Cancer 64 (1995) 27
23. Lowe S.W., Ruley H.E., Jacks T., et al. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74 (1993) 957
24. Ayers M., Symmans W.F., Stec J., et al. Complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 22 (2004) 2284
25. Chang J.C., Wooten E.C., Tsimelzon A., et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362 (2003) 362